Daré Bioscience, Inc. (DARE:NASDAQ) closed at $0.646 on October 23, 2026, down 0.89% on the day. The stock trades 82.9% below its 52-week high of $3.78 and 3.3% above its 52-week low of $0.625. Over the past year, it lost 69.4%. Daré Bioscience, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, DARE closed higher on 104 days (41%). Its best day was April 16, 2026 (+51.96%) and its worst was August 14, 2026 (-32.12%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 4 times.
Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The company's lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company has a strategic collaboration with Novartis to develop nanoparticle-drug conjugates for various cancer tumor targets. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.
Find more stocks like DARE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.